Filing Flows › Citius Pharmaceuticals (CTXR) › Q1 FY26
Citius Pharmaceuticals (CTXR) Q1 FY26 earnings results (first quarter fiscal 2026)
10-Q filed Feb 13, 2026
Citius Pharmaceuticals (CTXR) reported revenue of $3.9M for the first quarter fiscal 2026 (Q1 FY26). Operating margin was -228.7%, net loss $9.4M (238.2% of revenue).
Citius Pharmaceuticals, Q1 FY26: revenue $3.9M, operating margin -228.7%, net loss $9.4M, operating cash flow −$13.0M. The chart follows the revenue to costs, profit and cash.
| Q1 FY26 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $3.9M | — | — |
| Operating profit | −$9.0M | — | — |
| Net earnings | −$9.4M | — | — |
| Operating cash flow | −$13.0M | — | — |
What changed
Revenue was $3.9M in Q1 FY26.
Gross margin was 80.0%. Operating costs exceeded revenue by $9.0M, an operating margin of -228.7%. The quarter ended with a net loss of $9.4M. Minority interests bore $1.2M of it: to shareholders the quarter was a loss of $8.2M.
Operating cash flow was −$13.0M. Non-cash charges added back $4.3M of share-based compensation. Working capital and other items used $7.9M.
Questions
What was Citius Pharmaceuticals' revenue in the first quarter fiscal 2026?
Citius Pharmaceuticals (CTXR) reported revenue of $3.9M for the first quarter fiscal 2026 (Q1 FY26).
Was Citius Pharmaceuticals profitable in the first quarter fiscal 2026?
Operating loss was $9.0M (-228.7% of revenue) and net loss $9.4M.